ViiV HIV medicines receive positive EU opinion for younger children

ViiV Healthcare’s HIV medicines Tivicay and Dovato have received positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending extensions to their use in younger children, including eligible newborns.

If approved by the European Commission, the recommendations would expand access to dolutegravir-based treatment for children living with HIV, including a dispersible formulation of the two-drug combination dolutegravir/lamivudine.

The CHMP has recommended extending the indication for Tivicay (dolutegravir) dispersible tablets, in combination with other antiretroviral medicines, to include term neonates from birth weighing at least 2kg. The medicine is already approved for use in older children, adolescents and adults.

If approved, Tivicay would be the first second-generation integrase strand transfer inhibitor (INSTI) available in the EU for eligible newborns.

The committee has also recommended approval of a new dispersible tablet formulation of Dovato (dolutegravir/lamivudine) for children aged at least three months and weighing from 6kg to less than 25kg. The single-tablet, two-drug regimen could provide a new treatment option for younger children who meet the eligibility criteria.

A further recommendation would extend the existing film-coated Dovato tablet indication to children weighing at least 20kg. Both Dovato recommendations apply to patients with no known or suspected resistance to the integrase inhibitor class or lamivudine.

Evidence supporting the recommendations

The Tivicay application was supported by data from IMPAACT 2023, a study sponsored by the Division of AIDS and funded by the US National Institutes of Health. Pharmacokinetic modelling incorporating additional paediatric data indicated that dolutegravir could achieve therapeutic drug levels in term neonates, with no new safety findings identified compared with older paediatric populations.

Evidence for Dovato included the Penta-21 paediatric and adult pharmacokinetic study and the DANCE study, alongside data extrapolated from the adult GEMINI and TANGO trials. These studies supported the benefit-risk profile of dolutegravir/lamivudine in treatment-naïve and virologically suppressed paediatric populations.

ViiV reported that the safety and tolerability profiles of both treatments were consistent with those already established in older children and adults.

Jean van Wyk, chief medical officer at ViiV Healthcare, said: “Children living with HIV require lifelong care, making continued innovation essential. If approved, Tivicay would become the first second-generation integrase inhibitor to offer eligible newborns dolutegravir-based treatment, while Dovato would bring the first single tablet, two-drug regimen option to eligible younger children.”

He added: “These positive CHMP opinions mark an important step towards expanding age-appropriate, INSTI-based treatment options for children and advancing our goal of offering greater choice in HIV care, so more people living with HIV can benefit from innovative treatment options at every stage of life.”

Addressing gaps in paediatric HIV treatment

The recommendations come against a backdrop of continuing inequalities in access to HIV treatment among children. According to figures cited by ViiV, around 50% of untreated infants living with HIV die before their second birthday, while only 55% of children living with HIV were receiving antiretroviral therapy in 2024.

The European Commission is expected to make decisions on both applications in the first quarter of 2027.

A paediatric application for dolutegravir/lamivudine is also under review in the US, with a decision expected in the same quarter.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox